Neurokinin-3 peptide instead of neurokinin-1 synergistically exacerbates kainic acid-inducing degeneration of neurons in the substantia nigra of mice

Journal of Neurochemistry

Volumn 105, Issue 1, 2008, Pages 203-216

  Chen, Liang Wei ^a   Wang, Yan Qin ^a   Bian, Gan Lan ^a   Wei, Li Chun ^b   Yung, Kin Lam ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Basal ganglia; Dopaminergic neurons; Excitotoxicity; Neurokinins; Parkinson's disease

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; KAINIC ACID; N [ALPHA (METHOXYCARBONYL)BENZYL] 2 PHENYL 4 QUINOLINECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; PROTEIN SUBUNIT; SENKTIDE; SEPTIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG INHIBITION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SUBSTANTIA NIGRA;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELLS, CULTURED; DRUG SYNERGISM; KAINIC ACID; MALE; MICE; MICE, INBRED STRAINS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; ORGANIC CHEMICALS; PEPTIDE FRAGMENTS; PYRROLIDONECARBOXYLIC ACID; QUINOLINES; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-3; SUBSTANCE P; SUBSTANTIA NIGRA; TETRAZOLIUM SALTS; THIAZOLES;

MUS;

EID: 41149084961     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05132.x     Document Type: Article

References (70)

1. Abercombie M. (1946) Estimation of nuclear population from microtome sections. Anat. Rec. 94, 239 247.
2. Albers D. S., Weiss S. W., Iadarola M. J. Standaert D. G. (1999) Immunohistochemical localization of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience 89, 209 220.
3. Alonso R., Fournier M., Carayon P., Petitpretre G., Le Fur. G. Soubrie P. (1996) Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures. Eur. J. Neurosci. 8, 801 808.
4. Arai H. Emson P. C. (1986) Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res. 399, 240 249.
5. Arenas E., Alberch J., Perez-Navarro E., Solsona C. Marsal J. (1991) Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum. J. Neurosci. 11, 2332 2338.
6. Baguna J., Salo E. Romero R. (1989) Effects of activators and antagonists of the neuropeptides substance P and substance K on cell proliferation in planarians. Int. J. Dev. Biol. 33, 261 266.
7. Bannon M. J., Brownschidle L. A., Tian Y., Whitty C. J., Poosch M. S., D'sa C. Moody C. A. (1995) Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res. 695, 19 24.
8. Barker R. (1991) Substance P and neurodegenerative disorders. A speculative review. Neuropeptides 20, 73 78.
9. Barker R. (1996) Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Rev. Neurosci. 7, 187 214.
10. Beal M. F. (1992) Mechanism of excitatory in neurologic disease. FASEB J. 6, 3338 3344.
11. Bian G. L., Wei L. C., Shi M., Wang Y. Q., Cao R. Chen L. W. (2007) Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methy-4-phenyl-1,2,3,6-tetrahydropyrindine-treated C57BL/6 mice. Brain Res. 1150, 55 61.
12. Blandini F., Porter R. H. Greenamyre J. T. (1996) Glutamate and Parkinson's disease. Mol. Neurobiol. 12, 73 94.
13. Bolam J. P., Ingham C. A., Izzo P. N., Levey A. I., Rye D. B., Smith A. D. Wainer B. H. (1986) Substance P-containing terminals in synaptic contact with cholinergic neurons in the neostriatum and basal forebrain: a double immunocytochemical study in the rat. Brain Res. 397, 279 289.
14. Calvo N., Reiriz J., Perez-Navarro E. Alberch J. (1996) Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity instriatal cultures. Brain Res. 740, 323 328.
15. Chen L. W., Guan Z. L. Ding Y. Q. (1998) Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): a double immunocytochemical study in the rat. Brain Res. 780, 150 154.
16. Chen L. W., Wei L. C., Lang B., Ju G. Chan Y. S. (2001a) Differential expression of AMPA receptor subunits in dopamine neurons of the rat brain: a double immunocytochemical study. Neuroscience 106, 149 160.
17. Chen L. W., Wei L. C., Liu H. L., Ding Y. Q., Zhang H., Rao Z. R., Ju G. Chan Y. S. (2001b) Cholinergic neurons expressing neuromedin K receptor (NK3) in the basal forebrain of the rat: a double immunofluorescence study. Neuroscience 103, 413 422.
18. Chen L. W., Wei L. C., Qiu Y., Liu H. L., Rao Z. R., Ju G. Chan Y. S. (2002) Significant up-regulation of nestin protein in the neostriatum of MPTP-treated mice: are the striatal astrocytes regionally activated after systemic MPTP administration? Brain Res. 925, 9 17.
19. Chen L. W., Hu H. J., Liu H. L., Yung K. L. Chan Y. S. (2004a) Identification of BDNF in nestin- expressing astroglial cells in the neostriatum of MPTP-treated mice. Neuroscience 126, 941 953.
20. Chen L. W., Yung K. K. L. Chan Y. S. (2004b) Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr. Drug Targets 5, 197 206.
21. Chen L. W., Yung K. L. Chan Y. S. (2005) Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease. Curr. Drug Targets 6, 821 833.
22. Chen L. W., Zhang J. P., Shum D. K. Y. Chan Y. S. (2006) Localization of NGF, NT3 and GDNF in nestin-expressing reactive astrocytes in the caudate-putamen of MPTP-treated C57/BL mice. J. Comp. Neurol. 497, 898 909.
23. Coggeshall R. E. Lekan H. A. (1996) Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J. Comp. Neurol. 364, 6 15.
24. Constantinidis J., Bouras C. Richard J. (1983) Putative peptide neurotransmitters in human neuropathology: are view of topography and clinical implications. Clin. Neuropharmacol. 2, 47 54.
25. Ding Y. Q., Shigemoto R., Takada M., Ohishi H., Nakanishi S. Mizuno N. (1996) Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J. Comp. Neurol. 364, 290 310.
26. Dougherty P. M. Willis W. D. (1991) Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined micro-iontophoretic application of N-methyl-D-aspartic acid and substance P. Pain 47, 85 93.
27. Dunnet S. B. Bjorklund A. (1991) Staging and dissection of rat embryos, in Neural Transplantation: A Practical Approach (Rickwood D. Hames B. D., eds pp. 1 19. IRL Oxford University Press, Oxford.
28. Emson P. C., Arregui A., Clement-Jones V., Sandberg B. E. Rossor M. (1980) Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res. 199, 147 160.
29. Fernandez A., DeCeballos M. L., Jenner P. Marsden C. D. (1994) Neurotensin, substance P, delta and mu-opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 61, 73 79.
30. Fernandez-Espejo E. (2004) Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol. Neurobiol. 29, 15 30.
31. Futami T., Hatanaka Y., Matsushita K. Furuya S. (1998) Expression of substance P receptor in the substantia nigra. Mol. Brain Res. 54, 183 198.
32. Guzman R. G., Kendrick K. M. Emson P. C. (1993) Effect of substance P on acetylcholine and dopamine release in the rat striatum: a microdialysis study. Brain Res. 622, 147 154.
33. Humpel C., Saria A. Regoli D. (1991) Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism. Eur. J. Pharmacol. 195, 107 114.
34. Kaneko T., Shigemoto R., Nakanishi S. Mizuno N. (1993) Substance P receptor-immunoreactive neurons in the rat neostriatum are segregated into somatostatinergic and cholinergic aspiny neurons. Brain Res. 631, 297 303.
35. Kaneko S., Hikida T., Watanabe D., Ichinose H., Nagatsu T., Kreitman R. J., Pastan I. Nakanishi S. (2000) Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 289, 633 637.
36. Kawaguchi T., Wilson C. J., Augood S. J. Emson P. C. (1995) Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci. 18, 527 535.
37. Kemel M. L., Perez S., Godeheu G., Soubrie P. Glowinski J. (2002) Facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after acute and chronic suppression of dopaminergic transmission in the matrix of the rat striatum. J. Neurosci. 22, 1929 1936.
38. Lee C. R. Tepper J. M. (2007) Morphological and physiological properties of parvalbumin- and calretinin-containing gamma-aminobutyric acidergic neurons in the substantia nigra. J. Comp. Neurol. 500, 958 972.
39. Liberto C. M., Albrecht P. J., Herx L. M., Yong V. W. Levison S. W. (2004) Pro-regenerative properties of cytokine-activated astrocytes. J. Neurochem. 89, 1092 1100.
40. Lieberman D. N. Mody I. (1998) Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. J. Neurophysiol. 80, 113 119.
41. Mantha A. K., Moorthy K., Cowsik S. M. Baquer N. Z. (2006) Neuroprotective role of neurokinin B (NKB) on beta-amyloid (25-35) induced toxicity in aging rat brain synaptosomes: involvement in oxidative stress and excitotoxicity. Biogerontology 7, 1 17.
42. Marco N., Thirion A., Mons G., Bougault I., Le-Fur G., Soubrie P. Steinberg R. (1998) Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32, 481 488.
43. Marksteiner J., Sperk G. Krause J. E. (1992) Distribution of neurons expressing neurokinin B in the rat brain: immunohistochemistry and in situ hybridization. J. Comp. Neurol. 317, 341 356.
44. Mattioli R., Schwarting R. K. Huston J. P. (1992) Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11. Neuroscience 48, 595 605.
45. Mendez I., Elisevich K. Flumerfelt B. (1992) Substance P synaptic interactions with GABAergic and dopaminergic neurons in rat substantia nigra: an ultrastructural double-labeling immunocytochemical study. Brain Res. Bull. 28, 557 563.
46. Mussap C. J., Geraghty D. P. Burcher E. (1993) Tachykinin receptors: a radioligand binding perspective. J. Neurochem. 60, 1987 2009.
47. Nakanishi S. (1991) Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14, 123 136.
48. Nakanishi S. (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597 603.
49. Otsuka M. Yoshioka K. (1993) Neurotransmitter function of mammalian tachykinins. Physiol. Rev. 73, 229 308.
50. Parent A., Cicchetti F. Beach T. G. (1995) Striatal neurons displaying substance P (NK1) receptor immunoreactivity in human and nonhuman primates. Neuroreport 6, 721 724.
51. Paxinos G. Franklin K. B. J. (2001) The Mouse Brain in Stereotaxic Coordinates, 2nd Edn. Academic Press, New York.
52. Raffa R. B. (1998) Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Neurosci. Behav. Rev. 22, 789 813.
53. Randic M., Hecimovic H. Ryu P. D. (1990) Substance P modulates glutamate-induced currents in acutely isolated rat spinal dorsal horn neurones. Neurosci. Lett. 117, 74 80.
54. Sanberg P. R., Emerich D. F., Aebischer P., Amisetti S. M., Ouellette W., Koutouzis T. K., Cahill D. W. Norman A. B. (1993) Substance P containing polymer implants protect against striatal excitotoxicity. Brain Res. 628, 327 329.
55. + channel expression in microglia via distinct signalling pathways. Eur. J. Neurosci. 14, 463 473.
56. Schmued L. C. Hopkins K. J. (2000) Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol. Pathol. 28, 91 99.
57. Schmued L. C., Albertson C. William S. J. (1997) Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751, 37 46.
58. Schmued L. C., Stowers C. C., Scallet A. C. Xu L. (2005) Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res. 1035, 24 31.
59. Severini C., Ciotti M. T., Mercanti D., Barbato C. Calissano P. (2003) A tachykinin-like factor increases glutamate toxicity in rat cerebellar granule cells. Neuropharmacology 44, 117 124.
60. Smith Y., Bevan M. D., Shink E. Bolam J. P. (1998) Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 86, 353 387.
61. Sutoo D., Akiyama K. Yabe K. (2000) Quantitative maps of GABAergic and glutamatergic neuronal systems in the human brain. Hum. Brain Mapp. 11, 93 103.
62. Vila M., Jackson-Lewis V., Guegan C., Wu D. C., Teismann P., Choi D. K., Tieu K. Przedborski S. (2001) The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14, 483 489.
63. Wade T. V. Schneider J. S. (2001) Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs. J. Neurosci. 21, 4901 4907.
64. Wang Y. Q. Hu. H. J., Cao R. Chen L. W. (2005) Differential co-localization of neurokinin-3 receptor and NMDA/AMPA receptor subunits in neurons of the substantia nigra of C57/BL mice. Brain Res. 1053, 207 212.
65. Wenk G. L., Rance N. E. Mobley S. L. (1995) Effects of excitatory amino acid lesions upon neurokinin B and acetylcholine neurons in the nucleus basalis of the rat. Brain Res. 679, 8 14.
66. Wenk G. L., Zajaczkowski W. Danysz W. (1997) Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav. Brain Res. 83, 129 133.
67. Whitty C. J., Kapatos G. Bannon M. J. (1993) Neurotrophic effects of substance P on hippocampal neurons in vitro. Neurosci. Lett. 164, 141 144.
68. Williams R. W. Rakic P. (1988) Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J. Comp. Neurol. 278, 344 352.
69. Wyss-Coray T. Mucke L. (2002) Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35, 419 432.
70. Yu J., Wang J., Lud Cadet J. Angulo J. A. (2004) Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine- induced neurotoxicity in the mouse brain. Brain Res. 1007, 124 131.